Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radiation in Solitary Bone Plasmacytoma
NCT03196401Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2017
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab in solitary bone plasmacytoma (SBP), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Jul 2017; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
solitary bone plasmacytoma (SBP)
Beyond the preview
Go deeper on NCT03196401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196401.